Peptinov is a Paris-based biotech start-up founded by Prof. Jean-François Zagury to develop innovative vaccines against non-infectious diseases (auto-immmune diseases, cancer, chronic pain).

September 2017

Jean-Pierre Salles, Pharm.D., joined Peptinov as R&D Director. Jean-Pierre Salles is an expert in peptide synthesis and vaccine development.

June 2017

Peptinov released an article on the identification of an oral anti-TNFa small molecule inhibitor in Scientific Reports (Nature Publishing Group). Article available on Scientific Reports’ website.

May 2017

Peptinov signs a collaboration agreement with a leading Animal Health corporation.

March 2017

Peptinov starts the development of several anti-cancer vaccines.

January 2016

Peptinov released an article on the safety, immunogenicity and efficacy of its anti-IL-6 active immunotherapy candidate in non-human primates in Scientific Reports (Nature Publishing Group). Article available on Scientific Reports’ website.

June 2014

Peptinov’s R&D team published an article in Arthritis Research & Therapy, describing the protective effect of Peptinov’s PPV-06 vaccine against systemic sclerosis in mice.

December 2013 

Selection by Direction Générale de l’Armement (DGA) for a RAPID grant to develop Peptinov’s anti-TNF small molecule inhibitors, in collaboration with industrial partners, over the following 3 years.

October 2013

Laureate, FUI national grant program for the development of Peptinov’s anti-IL-1 vaccine, ensuring financing for this R&D program (performed in collaboration with industrial and academic partners) over the following 4 years.

March 2013 

Relocation of Peptinov’s laboratories to the Cochin Biotech Business Accelerator on the campus of Cochin Hospital.


The Cochin Biotech Business Accelerator hosting Peptinov’s labs.


June 2010

Move of Peptinov’s laboratories to Paris Biotech incubator at Cochin Hospital, Paris.

November 2009 

Creation of Peptinov.